Technical Analysis for BGNE - BeiGene, Ltd.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 129.52 | -1.85% | -2.44 |
Earnings due: May 2
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Multiple of Ten Bearish | Other | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Slingshot Bearish | Bearish Swing Setup | -1.85% | |
| Lower Bollinger Band Walk | Weakness | -1.85% | |
| Lower Bollinger Band Touch | Weakness | -1.85% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 19 hours ago |
| Down 3% | about 20 hours ago |
| Fell Below Lower Bollinger Band | about 20 hours ago |
| Slingshot Bearish Entry | about 20 hours ago |
| Fell Below Previous Day's Low | about 20 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/02/2024
BeiGene, Ltd. Description
BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People's Republic of China. The company's clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers. Its preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company was founded in 2010 and is based in Camana Bay, Cayman Islands.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Monoclonal Antibodies Monoclonal Antibody Lymphoma Oncogenes Protein Kinase Bruton's Tyrosine Kinase Ras Subfamily Rp1
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 266.665 |
| 52 Week Low | 126.9681 |
| Average Volume | 214,639 |
| 200-Day Moving Average | 177.42 |
| 50-Day Moving Average | 154.79 |
| 20-Day Moving Average | 147.10 |
| 10-Day Moving Average | 140.68 |
| Average True Range | 5.36 |
| RSI (14) | 26.47 |
| ADX | 28.67 |
| +DI | 13.09 |
| -DI | 39.25 |
| Chandelier Exit (Long, 3 ATRs) | 154.28 |
| Chandelier Exit (Short, 3 ATRs) | 143.05 |
| Upper Bollinger Bands | 165.00 |
| Lower Bollinger Band | 129.20 |
| Percent B (%b) | 0.01 |
| BandWidth | 24.34 |
| MACD Line | -7.39 |
| MACD Signal Line | -5.23 |
| MACD Histogram | -2.1508 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 135.34 | ||||
| Resistance 3 (R3) | 135.14 | 132.99 | 134.37 | ||
| Resistance 2 (R2) | 132.99 | 131.51 | 133.10 | 134.05 | |
| Resistance 1 (R1) | 131.26 | 130.60 | 130.19 | 131.46 | 133.73 |
| Pivot Point | 129.11 | 129.11 | 128.58 | 129.21 | 129.11 |
| Support 1 (S1) | 127.38 | 127.63 | 126.30 | 127.58 | 125.31 |
| Support 2 (S2) | 125.23 | 126.71 | 125.33 | 124.99 | |
| Support 3 (S3) | 123.49 | 125.23 | 124.67 | ||
| Support 4 (S4) | 123.70 |
